Table 1. Baseline Characteristics of the Study Patients.
| Variable | Value (n=10) |
|---|---|
| Age (yr) | 52.9±9.6 |
| Male sex | 5 (50.0) |
| Time since diagnosis (yr) | 7.2±5.9 |
| Ulcer location | |
| Terminal ileum | 2 (20.0) |
| IC valve | 5 (50.0) |
| Colon | 1 (10.0) |
| Anastomosis site | 2 (20.0) |
| Deep ulcer (vs. shallow ulcer) | 6 (60.0) |
| Volcano ulcer (vs. oval ulcer) | 3 (30.0) |
| Ulcer size (cm) | |
| 1–2 | 4 (40.0) |
| 2–3 | 1 (10.0) |
| ≥3 | 5 (50.0) |
| No. of surgery | 1.4±2.3 |
| No. of perforation | 0.8±1.0 |
| Extraintestinal manifestation | |
| Oral ulceration | 10 (100.0) |
| Genital ulceration | 4 (40.0) |
| Uveitis | 1 (10.0) |
| Skin lesion | 6 (60.0) |
| Arthritis | 7 (70.0) |
| Nervous system | 0 |
| Vascular system | 0 |
| Previous medication | |
| Thiopurine | 7 (70.0) |
| Anti-TNF-α | |
| Infliximab | 3 (30.0) |
| Adalimumab | 2 (20.0) |
| Infliximab, adalimumab | 1 (10.0) |
| DAIBD total score | 82.5±36.8 |
| CRP level (mg/L) | 57.8±36.0 |
| ESR level (mm/hr) | 38.0±36.1 |
Values are presented as mean±SD or number (%).
IC, ileocecal; TNF, tumor necrosis factor; DAIBD, disease activity index for intestinal Behçet's disease.